Sugi Predict

Sugi Predict / Compounds / SCHEMBL870792

SCHEMBL870792

SCHEMBL870792

O=C(O)c1cn2cc(F)ccc2n1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.59
▸ PTGS2 P35354 1/20 0.59
▸ EGLN1 Q9GZT9 5/20 0.52
▸ APP P05067 1/20 0.46
▸ MAP3K5 Q99683 1/20 0.46
▸ CLK1 P49759 1/20 0.46
▸ DYRK1A Q13627 1/20 0.46
▸ METTL3 Q86U44 2/20 0.43
▸ CYP11B1 P15538 3/20 0.42
▸ CYP11B2 P19099 3/20 0.42
▸ ALDH1A3 P47895 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ HRH4 Q9H3N8 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1422913 0.98 PTGS1 (0.57) PTGS1PTGS2EGLN1APPMAP3K5
SCHEMBL21001625 0.89 EGLN1 (0.67) PTGS1PTGS2EGLN1APPCLK1
SCHEMBL16104299 0.87 CLK1 (0.55) PTGS1PTGS2EGLN1APPMAP3K5
SCHEMBL8176307 0.86 APP (0.48) PTGS1PTGS2EGLN1APPMAP3K5
SCHEMBL5338541 0.86 EGLN1 (0.47) PTGS1PTGS2EGLN1APPMAP3K5
SCHEMBL2086460 0.84 PTGS1 (0.50) PTGS1PTGS2EGLN1MAP3K5METTL3
SCHEMBL21033156 0.82 EGLN1 (0.55) PTGS1PTGS2EGLN1CLK1DYRK1A
SCHEMBL2638074 0.81 PTGS1 (0.59) PTGS1PTGS2EGLN1APPMAP3K5
SCHEMBL28626437 0.81 PTGS1 (0.59) PTGS1PTGS2EGLN1APPCLK1
SCHEMBL9753842 0.81 PTGS1 (0.59) PTGS1PTGS2EGLN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 — — US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 — — CN disclosed
EP-3452456-B1 BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-05 — — EP disclosed
CN-109641854-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-02-03 — — CN disclosed
CN-113905607-B Heterocyclic compound and harmful arthropod control composition containing same 住友化学株式会社 2022-12-27 — — CN disclosed
US-20220106281-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-04-07 — — US disclosed
CN-113905607-A Heterocyclic compound and harmful arthropod control composition containing same 住友化学株式会社 2022-01-07 — — CN disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 — — US disclosed
US-10913727-B2 Modulators of the integrated stress pathway ABBVIE INC. (US) 2021-02-09 — — US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 — — EP disclosed
EP-1430050-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY AstraZeneca AB (SE) 2004-06-23 — — EP disclosed
US-20040014783-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2004-01-22 — — US disclosed
US-20040006080-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2004-01-08 — — US disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 — — WO disclosed
WO-2003024962-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY ASTRAZENECA AB (SE) 2003-03-27 — — WO disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 — — US disclosed
EP-1274701-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-01-15 — — EP disclosed
US-20020077337-A1 Chemical compounds ASTRAZENECA AB (SE) 2002-06-20 — — US disclosed
WO-2001077101-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077337-A1 Chemical compounds CCR3, CCR1, CCR4 PTGS1 178/4885PTGS2 535/4885EGLN1 1101/4885
US-10913727-B2 Modulators of the integrated stress pathway ATF4, ATF1, DDIT3 PTGS1 321/4885PTGS2 324/4885EGLN1 1913/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PTGS1 321/4885PTGS2 324/4885EGLN1 1913/4885
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 PTGS1 2236/4885PTGS2 3251/4885EGLN1 3080/4885
US-20220106281-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PTGS1 321/4885PTGS2 324/4885EGLN1 1913/4885
US-20040006080-A1 Chemical compounds CCR3, CCR1, CCR4 PTGS1 178/4885PTGS2 535/4885EGLN1 1101/4885
US-20040014783-A1 Chemical compounds CCR3, CCR1, CCR4 PTGS1 178/4885PTGS2 535/4885EGLN1 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.